T D Gould

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Psychiatric endophenotypes and the development of valid animal models
    T D Gould
    Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, National Institute of Mental Health, NIH, HHS, Bethesda, MD 20892, USA
    Genes Brain Behav 5:113-9. 2006
  2. ncbi request reprint Targeting glycogen synthase kinase-3 as an approach to develop novel mood-stabilising medications
    Todd D Gould
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892 3711, USA
    Expert Opin Ther Targets 10:377-92. 2006
  3. ncbi request reprint Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders
    Todd D Gould
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, NIH, Bethesda, MD 20892 3711, USA
    Curr Drug Targets 7:1399-409. 2006
  4. ncbi request reprint Strain differences in lithium attenuation of d-amphetamine-induced hyperlocomotion: a mouse model for the genetics of clinical response to lithium
    Todd D Gould
    Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, National Institute of Mental Health, NIH, HHS, Bethesda, MD 20892 3711, USA
    Neuropsychopharmacology 32:1321-33. 2007
  5. ncbi request reprint Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs
    Todd D Gould
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, Bethesda, MD 20892, USA
    Neuropsychopharmacology 30:1223-37. 2005
  6. ncbi request reprint Emerging experimental therapeutics for bipolar disorder: clues from the molecular pathophysiology
    J A Quiroz
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, Bethesda, MD 20892, USA
    Mol Psychiatry 9:756-76. 2004
  7. ncbi request reprint Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers
    T D Gould
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, Bethesda, MD 20892, USA
    Mol Psychiatry 9:734-55. 2004
  8. ncbi request reprint Possible involvement of the ERK signaling cascade in bipolar disorder: behavioral leads from the study of mutant mice
    H Einat
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892 4405, USA
    Drug News Perspect 16:453-63. 2003
  9. ncbi request reprint Mood stabilizers target cellular plasticity and resilience cascades: implications for the development of novel therapeutics
    Rosilla F Bachmann
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, Bethesda, MD, USA
    Mol Neurobiol 32:173-202. 2005
  10. ncbi request reprint Toward constructing an endophenotype strategy for bipolar disorders
    Gregor Hasler
    Mood and Anxiety Disorders Program, National Institute of Mental Health, Bethesda, Maryland, USA
    Biol Psychiatry 60:93-105. 2006

Collaborators

Detail Information

Publications32

  1. ncbi request reprint Psychiatric endophenotypes and the development of valid animal models
    T D Gould
    Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, National Institute of Mental Health, NIH, HHS, Bethesda, MD 20892, USA
    Genes Brain Behav 5:113-9. 2006
    ....
  2. ncbi request reprint Targeting glycogen synthase kinase-3 as an approach to develop novel mood-stabilising medications
    Todd D Gould
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892 3711, USA
    Expert Opin Ther Targets 10:377-92. 2006
    ..A number of recent reports suggest that it is possible to develop selective, small-molecule GSK-3 inhibitors...
  3. ncbi request reprint Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders
    Todd D Gould
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, NIH, Bethesda, MD 20892 3711, USA
    Curr Drug Targets 7:1399-409. 2006
    ..The evidence described in this review suggests that regulating GSK-3 may represent a target for novel medications to treat mood disorders...
  4. ncbi request reprint Strain differences in lithium attenuation of d-amphetamine-induced hyperlocomotion: a mouse model for the genetics of clinical response to lithium
    Todd D Gould
    Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, National Institute of Mental Health, NIH, HHS, Bethesda, MD 20892 3711, USA
    Neuropsychopharmacology 32:1321-33. 2007
    ....
  5. ncbi request reprint Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs
    Todd D Gould
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, Bethesda, MD 20892, USA
    Neuropsychopharmacology 30:1223-37. 2005
    ..In this regard, as is discussed, there is a major effort underway to develop novel, specific, GSK-3 inhibitors...
  6. ncbi request reprint Emerging experimental therapeutics for bipolar disorder: clues from the molecular pathophysiology
    J A Quiroz
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, Bethesda, MD 20892, USA
    Mol Psychiatry 9:756-76. 2004
    ..While the task of developing novel medications for bipolar disorder is truly daunting, these and similar approaches will ultimately lead to better medications for the millions who suffer from this devastating illness...
  7. ncbi request reprint Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers
    T D Gould
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, Bethesda, MD 20892, USA
    Mol Psychiatry 9:734-55. 2004
    ....
  8. ncbi request reprint Possible involvement of the ERK signaling cascade in bipolar disorder: behavioral leads from the study of mutant mice
    H Einat
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892 4405, USA
    Drug News Perspect 16:453-63. 2003
    ....
  9. ncbi request reprint Mood stabilizers target cellular plasticity and resilience cascades: implications for the development of novel therapeutics
    Rosilla F Bachmann
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, Bethesda, MD, USA
    Mol Neurobiol 32:173-202. 2005
    ..This article also discusses approaches to develop novel treatments specifically for bipolar disorder...
  10. ncbi request reprint Toward constructing an endophenotype strategy for bipolar disorders
    Gregor Hasler
    Mood and Anxiety Disorders Program, National Institute of Mental Health, Bethesda, Maryland, USA
    Biol Psychiatry 60:93-105. 2006
    ..Studies to evaluate candidate endophenotypes with respect to specificity, heritability, temporal stability, and prevalence in unaffected relatives are encouraged...
  11. ncbi request reprint Endophenotypes in bipolar disorder
    Robert H Lenox
    Neuropsychopharmacology Program, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Am J Med Genet 114:391-406. 2002
    ..Furthermore, lithium has been shown to regulate circadian cycles in diverse species, including humans, possibly through inhibition of glycogen synthase kinase 3-beta (GSK-3beta), a known target of lithium...
  12. ncbi request reprint Beta-catenin overexpression in the mouse brain phenocopies lithium-sensitive behaviors
    Todd D Gould
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892 3711, USA
    Neuropsychopharmacology 32:2173-83. 2007
    ..By associating the behavioral effects of lithium with beta-catenin levels, these data suggest that increasing beta-catenin might be a novel therapeutic strategy for mood disorders...
  13. pmc The behavioral actions of lithium in rodent models: leads to develop novel therapeutics
    Todd D Gould
    The Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, National Institute of Mental Health, NIH, HHS, Bldg 35, Rm 1C 912, 35 Convent Drive, Bethesda, MD 20892 3711, USA
    Neurosci Biobehav Rev 31:932-62. 2007
    ....
  14. pmc Animal models of bipolar disorder and mood stabilizer efficacy: a critical need for improvement
    Todd D Gould
    Mood and Anxiety Program, Department of Psychiatry, University of Maryland School of Medicine, 701 West Pratt Street, Suite 388, Baltimore, Maryland 21201, USA
    Neurosci Biobehav Rev 31:825-31. 2007
    ..Regardless of the path taken by different researchers to develop better models, we believe that this area of work requires additional attention not only from researchers but also from funding agencies...
  15. pmc Involvement of AMPA receptors in the antidepressant-like effects of lithium in the mouse tail suspension test and forced swim test
    Todd D Gould
    Laboratory of Molecular Pathophysiology and Experimental Therapeutics, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA
    Neuropharmacology 54:577-87. 2008
    ..Lithium may exert its antidepressant effects in humans through AMPA receptors, thus further supporting a role of targeting AMPA receptors as a therapeutic approach for the treatment of depression...
  16. pmc Generation and behavioral characterization of beta-catenin forebrain-specific conditional knock-out mice
    Todd D Gould
    Laboratory of Molecular Pathophysiology and Experimental Therapeutics, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA
    Behav Brain Res 189:117-25. 2008
    ..Alternatively, regulating beta-catenin may modulate drug effects rather than being a model of mood disorder pathophysiology per se...
  17. ncbi request reprint AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test
    Todd D Gould
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892 3711, USA
    Int J Neuropsychopharmacol 7:387-90. 2004
    ....
  18. ncbi request reprint The Wnt signaling pathway in bipolar disorder
    Todd D Gould
    Neuroscientist 8:497-511. 2002
    ..The future development of selective GSK-3beta inhibitors may have considerable utility not only for the treatment of bipolar disorder but also for a variety of classical neurodegenerative disorders...
  19. ncbi request reprint The endophenotype concept in psychiatry: etymology and strategic intentions
    Irving I Gottesman
    Department of Psychiatry, University of Minnesota Medical School, Minneapolis 55454, USA
    Am J Psychiatry 160:636-45. 2003
    ..The authors discuss the etymology and strategy behind the use of endophenotypes in neuropsychiatric research and, more generally, in research on other diseases with complex genetics...
  20. ncbi request reprint Effects of a glycogen synthase kinase-3 inhibitor, lithium, in adenomatous polyposis coli mutant mice
    Todd D Gould
    Laboratory of Molecular Pathophysiology, National Institutes of Mental Health, 49 Convent Drive, Room B1EE16, Bethesda, MD 20892, USA
    Pharmacol Res 48:49-53. 2003
    ..These results are consistent with the available epidemiological evidence that long-term lithium therapy does not increase cancer morbidity or mortality, but rather is associated with reduced overall mortality in bipolar disorder...
  21. ncbi request reprint The role of the extracellular signal-regulated kinase signaling pathway in mood modulation
    Haim Einat
    Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892 4405, USA
    J Neurosci 23:7311-6. 2003
    ..These data suggest that the ERK pathway may mediate the antimanic effects of mood stabilizers...
  22. ncbi request reprint In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3
    Todd D Gould
    Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, National Institute of Mental Health, Bethesda, MD 20892 4405, USA
    Neuropsychopharmacology 29:32-8. 2004
    ..These results strongly suggest that lithium significantly inhibits brain glycogen synthase kinase-3 in vivo at concentrations relevant for the treatment of bipolar disorder...
  23. ncbi request reprint Signal transduction and genes-to-behaviors pathways in psychiatric diseases
    Husseini K Manji
    Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, NIMH, Bethesda, MD 20892, USA
    Sci STKE 2003:pe49. 2003
    ..It is likely that genetic findings in severe psychiatric disorders will continue to implicate direct and indirect modulation of critical intracellular signaling pathways...
  24. ncbi request reprint Glycogen synthase kinase-3: a target for novel bipolar disorder treatments
    Todd D Gould
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, NIH, Bethesda, MD 20892, USA
    J Clin Psychiatry 65:10-21. 2004
    ..We conclude with a discussion of the GSK-3 inhibitors furthest in development and the clinical trials that may emerge...
  25. ncbi request reprint The molecular medicine revolution and psychiatry: bridging the gap between basic neuroscience research and clinical psychiatry
    Todd D Gould
    J Clin Psychiatry 65:598-604. 2004
    ....
  26. ncbi request reprint Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis
    Yanlei Hao
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20892 4405, USA
    J Neurosci 24:6590-9. 2004
    ..This cascade of events provides a potential mechanism whereby mood stabilizers alleviate cerebral morphometric deficits associated with manic-depressive illness...
  27. ncbi request reprint Signaling networks in the pathophysiology and treatment of mood disorders
    Todd D Gould
    Laboratory of Molecular Pathophysiology, NIMH, National Institutes of Health, Building 49, Room B1EE16, Bethesda, MD 20892 4405, USA
    J Psychosom Res 53:687-97. 2002
    ..The systems discussed within this review have been implicated in neuroplastic processes and in modulation of many other cellular pathways, making them likely candidates for mediators of these findings...
  28. pmc DARPP-32: A molecular switch at the nexus of reward pathway plasticity
    Todd D Gould
    Laboratory of Molecular Pathophysiology, Building 35, Room 1C 912, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892 3711, USA
    Proc Natl Acad Sci U S A 102:253-4. 2005
  29. ncbi request reprint Post-mortem interval effects on the phosphorylation of signaling proteins
    Jianling Li
    Laboratory of Molecular Pathophysiology, Wayne State University School of Medicine, Detroit, MI, USA
    Neuropsychopharmacology 28:1017-25. 2003
    ..Thus, it appears that measurements (such as two-dimensional gel electrophoresis and functional assays) that rely on the phosphorylation state of proteins would be extremely sensitive to PMI...
  30. ncbi request reprint Targeting signal transduction pathways in the treatment of mood disorders: recent insights into the relevance of the Wnt pathway
    Todd D Gould
    Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, National Institute of Mental Health, NIH, HHS, Bethesda, Maryland 20892 3711, USA
    CNS Neurol Disord Drug Targets 6:193-204. 2007
    ..Future directions, aimed at understanding mood disorders and developing more efficacious treatments, are also discussed...
  31. ncbi request reprint Performance on a virtual reality spatial memory navigation task in depressed patients
    Neda F Gould
    Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, NIMH, Mark O Hatfield Clinical Research Center, 10 Center Dr, Bethesda, MD 20892, USA
    Am J Psychiatry 164:516-9. 2007
    ..Findings on spatial memory in depression have been inconsistent. A navigation task based on virtual reality may provide a more sensitive and consistent measure of the hippocampal-related spatial memory deficits associated with depression...
  32. ncbi request reprint Molecular effects of lithium
    Jorge A Quiroz
    Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, National Institute of Mental Health, NIH, Bethesda, Maryland 20892, USA
    Mol Interv 4:259-72. 2004
    ..Many of the new insights of lithium's actions may lead to the strategic development of improved therapeutics for the treatment of bipolar disorder...